Mutual of America Capital Management LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.2% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 208,973 shares of the biopharmaceutical company’s stock after acquiring an additional 12,254 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Gilead Sciences were worth $16,931,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC raised its holdings in Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after buying an additional 258,005 shares during the last quarter. Seizert Capital Partners LLC raised its holdings in Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after buying an additional 27,547 shares during the last quarter. Investment Centers of America Inc. raised its holdings in Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after buying an additional 1,958 shares during the last quarter. Northern Trust Corp raised its holdings in Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after buying an additional 116,780 shares during the last quarter. Finally, Fagan Associates Inc. raised its holdings in Gilead Sciences by 2.6% during the 2nd quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after buying an additional 845 shares during the last quarter. Hedge funds and other institutional investors own 76.23% of the company’s stock.

A number of research analysts have issued reports on the stock. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 7th. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. Vetr downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective on the stock. in a research report on Monday, September 4th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $85.11.

In related news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the transaction, the executive vice president now owns 70,988 shares in the company, valued at approximately $5,298,544.32. The disclosure for this sale can be found here. Insiders sold a total of 494,999 shares of company stock worth $37,404,139 over the last ninety days. Insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $75.57 on Friday. The firm has a market cap of $97,108.04, a PE ratio of 7.76, a PEG ratio of -1.25 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue was down 13.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.75 EPS. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.

WARNING: “Mutual of America Capital Management LLC Acquires 12,254 Shares of Gilead Sciences, Inc. (GILD)” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/mutual-of-america-capital-management-llc-acquires-12254-shares-of-gilead-sciences-inc-gild/1768991.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.